Faron Obtains Debt Funding from IPF Partners


Faron Pharmaceuticals Ltd. (AIM: FARN) (First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has entered into a secured debt agreement (“Funding Agreement”) with IPF Partners (“IPF”) to advance and accelerate its pipeline programs. The first tranche of EUR 10 million is agreed to be drawn today and is to be repaid quarterly over a five year term.

Read More

Next Post

Accenture and Microsoft to Assist Mount Sinai Health System on Five-Year Transformation Journey to Cloud

Accenture will collaborate with New York City’s largest academic medical system to help devise and securely execute its strategic cloud migration of clinical applications, including its Epic electronic health records system. Microsoft will provide quality assurance throughout this landmark academic center’s Azure migration process. Read More